References
- Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS23(4), 525–530 (2009).
- Tanner DC, Weinstein MP, Fedorciw B et al. Comparison of commercial kits for cryptococcal antigen. J. Clin. Microbiol.32(7), 1680–1684 (1994).
- Lindsley MD, Mekha N, Baggett HC et al. Evaluation of a newly developed lateral flow immunoassay for the diagnosis of Cryptococcosis. Clin. Infect. Dis.53(4), 321–325 (2011).
- Bekondi C, Bernede C, Passone N et al. Primary and opportunistic pathogens associated with meningitis in adults in Bangui, Central African Republic, in relation to human immunodeficiency virus serostatus. Int. J. Infect. Dis.10, 387–395 (2006).
- Lawn SD, Bekker LG, Myer L, Orrell C, Wood R. Cryptococcal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral program. AIDS19, 2050–2052 (2005).
- Etard JF, Ndiaye I, Thierry-Mieg M et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS20, 1181–1189 (2006).
- Jarvis JN, Meintjes G, Wood R, Jarrison TS. Testing but not treating: missed opportunities and lost lives in the South African anti-retroviral therapy programme. AIDS24, 1233–1235 (2010).
- French N, Gray K, Watera C et al. Crytpococcal infection in a cohort of HIV-1 infected Ugandan adults. AIDS16, 1031–1038 (2002).
- Jarvis JN, Lawn SD, Vogt M et al. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin. Infect. Dis.48, 856–862 (2009).
- Meya DB, Manabe YC, Castelnuovo B et al. Cost–effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4 cell count ≤100 cells/µl who start HIV therapy in resource-limited settings. Clin. Infect. Dis.51, 448–455 (2010).